Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
US8871202B2 · kind B2 · utility
1Cited by
102References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 27, 2011 |
| Grant date | Oct 28, 2014 |
| Priority date | — |
| Expiry date | Dec 4, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to use of anti-S1P agents, for example, humanized monoclonal antibodies, for prevention and/or treatment of pain, including neuropathic pain, hyperalgesia, allodynia, and chemotherapy-induced pain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.